Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-01-22
2010-10-12
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S347100
Reexamination Certificate
active
07812049
ABSTRACT:
The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using α1-adrenergic receptor (α1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.
REFERENCES:
patent: 4853216 (1989-08-01), Koslo et al.
patent: 6335023 (2002-01-01), Yu et al.
patent: 6824786 (2004-11-01), Yu et al.
patent: 2004/0220259 (2004-11-01), Yu et al.
patent: 2004/0242588 (2004-12-01), DeJovin et al.
patent: 2005/0020600 (2005-01-01), Scherer
patent: 2005/0222101 (2005-10-01), Hutterer
patent: 2005/0256204 (2005-11-01), Bitter, Sr.
patent: 2005/0271596 (2005-12-01), Friedman et al.
patent: 2005/0276830 (2005-12-01), DeJovin et al.
patent: 2005/0281772 (2005-12-01), Bromley et al.
patent: 2006/0171974 (2006-08-01), DeJovin et al.
patent: 2006/0264515 (2006-11-01), DeJovin et al.
patent: 2007/0048234 (2007-03-01), Waugh et al.
patent: 2007/0082070 (2007-04-01), Stookey et al.
patent: 2007/0225217 (2007-09-01), Chappell et al.
patent: 2007/0225631 (2007-09-01), Bowlin et al.
patent: 2009/0130027 (2009-05-01), Shanler et al.
Fisher, D.A. “Adverse Effects of Topical Corticosteroid Use”, West J. Med., 1995, vol. 162, pp. 123-126.
Shanler et al., Successful Treatment of the Erythema of Flushing of Rosacea Using a Topically Applied Selective α1Adrenergic Receptor Agonist, Oxymetazoline, 2007, Arch Dermatol. 143(11):1369-1371.
Leal, George; Miscellaneous e-mail communication (date unverified).
Crawford et al., Rosacea: I. Etiology, pathogenesis, and subtype classification, Sep. 2004, J. Am. Acad. Dermatol. 51(3):327-341.
Pelle et al., Rosacea: II. Therapy, Oct. 2004, Am. Acad. Dermatol. 51(4):499-512.
Wilkin et al., Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea, 2002, 46(4):584-587.
Plewig et al., Acne and Rosacea, Acne and Rosacea, 2ndRev. Ed., Springer-Verlag Berlin, pp. 433-475.
Wilkin, Why is flushing limited to a mostly facial curaneous distribution?, Aug. 1988, J. Am. Acad. Dermatol. 2(1):309-313.
Wilkin, Oral Thermal-Induced Flushing in Erythematotelangiectatic Rosacea, 1981, J. Invest. Dermatol. 76:15-18.
Parodi et al., Flusjng in Rosacea: An Experimental Approach, 1980, Archives of Dermatol. Res., Springer-Verlag, 269:269-273.
Ahlquist, A Study of the Adrenotropic Receptors, Jun. 1948, Adrenotropic Receptors 153:586-600.
Kirstein et al., Autonomic Nervous System Pharmacogenomics: A Progress Report, 2004, Pharmacol. Rev. 56(1):31-52.
Piascik et al., α1-Adrenergic Receptors: New Insights and Directions, 2001, J. Pharmacol. and Exper. Therap. 298(2):403-410.
Calzada et al., Alpha-Adrenoceptor Subtypes, 2001, Pharmacol. Res. 44(3):195-207.
Guimaraes et al., Vascular Adrenoceptors: An Update, 2001, Am. Soc. Pharmacol. and Exper. Therapeutics, Pharmacol. Rev. 53(2):319-356.
Hieble, Subclassification and Nomenclature of α-and β-Adrenoceptors, 2007, Curr. Topics in Medicinal Chem. 7:129-134.
Jarajapu et al., Functional Characterization of α1-Adrenoceptor Subtypes in Human Subcutaneous Resistance Arteries, 2001, J. Pharmacol. and Exp. Therapeutics 299(2):729-734.
Leech et al., Different α-adrenoceptor subtypes mediate constriction of arterioles and venules, 1996, Am. Phys. Soc., pp. H710-H722.
Chalothorn et al., Differences in the Cellular Localization and Agonist-Mediated Internatilization Properties of the α1-Adrenoceptor Subtypes, 2002, Molec. Pharmacol. 61(5):1008-1016.
Bishop, Recent Advances in the Discovery of α1-Adrenoceptor Agonists, 2007, Curr. Topics Med. Chem. 7:135-145.
Crassous et al., Interest of α2-Adrenergic Agonists and Antagonists in Clinical Practice: Background, Facts and Perspectives, 2007, Curr. Topics med. Chem. 7:187-194.
Gentili et al., Agonists and Antagonists Targeting the Different α2-Adrenoceptor Subtypes, 2007, Curr. Topics Med. Chem. 7:163-186.
Speake et al., 2-(Anilinomethyl)imidazolines as α1Adrenergic Receptor Agonists: α1aSubtype Selective 2′ Heteroaryl Compounds, 2003, Bioorganic & Med. Chem. Letters 13:1183-1186.
Pigini et al., Structure-Activity Relationship at α-Adrenergic Receptors Within a Series of Imidazoline Analogues of Cirazoline, 2000, Bioorganic & Med. Chem. 8:883-888.
Cross et al., Transdermal and Penetration of Vasoconstrictors-Present Understanding and Assessment of the Human Epidermal Flux and Retention of Free Bases and Ion-Pairs, Feb. 2003, Pharma. Res. 20(2):270-274.
Jenni, Information Connection: Tips on Treating Acne, http://www.mindconnection.com/library/health/acnecare.htm.
Scruggs et al., The teardrop sign: a rare dermatological reaction to brimonidine, 2004, Br. J. Ophthalmol 84:667.
Rona's Skin Remedies, Beauty and Style, http://beauty.ivillage.com/skinbody/facecare/0,,8h9s,00.html.
Peter Lama's Beauty Solutions, Tips for Beautiful Face and Body Skin, Beauty Magazine, http://www.lamasbeauty.com/beauty/solutions/tips—face—skin.htm.
Health Boards, http://www.healthboards.com/boards/showthread.php?t=5725&highlight=visine+zits.
Bratslavsky, DERMAdoctor, Skincare articles: your prescription for beautiful skin, http://www.dermadoctor.com/pages
ewsletter221.asp.
ACNE.ORG, http://www.acne.org/messageboard/index.php?showtopic=34267.
ACNETEAM.COM, http://www.acneteam.com/home-remedies-to-heal-acne-quick.html.
Tetrahydrozoline hydrochloride, http://www.sigmaaldrich.com/catalog/search/ProductDetail/SIGMA/T4264.
Bamford et al., “Rosacea: Current Thoughts on Origin” 2001, Seminars in Cutaneous Medicine and Surgery, 20(3):199-206.
Crawford et al. “Rosacea: I. Etiology, Pathogenesis, and Subtype Classification” 2004, J. Am. Acad. Dermatol., 51(3):324-41.
Cunliffe et al. “Clonidine and Facial Flushing in Rosacea” 1977, British Med. J., 105.
Sams “Untoward Response with Topical Fluoruracil” 1968, Arch. Dermatol. 97(1): 14-22.
Collagenex Corporation/IMS Demand Study as presented at The Fourth Annual Healthcare Conference. Nov. 27-28, 2007, New York, NY.
van Zuuren et al. “Systematic Review of Rosacea Treatments” 2007, J. Am. Acad. Dermatol. 56:107-115.
Powell “Clinical Practice: Rosacea” 2005, N. Engl. J. Med. 352(8):793-803.
Ondo Andrew
Shanler Stuart D.
Carter Kendra D
Padmanabhan Sreeni
Pepper Hamilton LLP
Vicept Therapeutics, Inc.
LandOfFree
Method and therapeutic/cosmetic topical compositions for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and therapeutic/cosmetic topical compositions for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and therapeutic/cosmetic topical compositions for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4217037